Program
vilagletistat
Also written as “ZED1227 + SIGE”, “TAK-227” and “ZED1227”.
Its studies are mostly in Celiac Disease · Non-alcoholic Fatty Liver Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. Falk Pharma | 21 open or running | phase 2since Mar 4, 2022 | Mar 4, 2022 | Aug 2027phase 2 · NCT07298343 |
| Takeda | 10 open or running | phase 1since Apr 6, 2023 | Apr 6, 2023 | none ahead |
Also a collaborator on its studies: takeda-development-center-americas-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 4, 2022First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Dr. Falk PharmaDr. Falk Pharma · NCT05305599 · 186 enrolled · Germany
- Apr 6, 2023Takeda's first study: phase 1 study in Healthy VolunteersNew to TakedaTakeda · NCT05818956 · 24 enrolled · United States
- Dec 17, 2025Phase 2 study in Celiac DiseaseDr. Falk Pharma · NCT07298343 · 356 planned · Germany
Ahead
- Aug 2027Primary completion: phase 2 study in Celiac DiseaseDr. Falk Pharma · NCT07298343
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07298343Celiac Disease · Germany | 2 | Recruiting | Dr. Falk Pharma | Aug 2027 | 356 |
| NCT05818956Healthy Volunteers · United States | 1 | Completed | Takeda | Jun 19, 2023 | 24 |
| NCT05305599Non-alcoholic Fatty Liver Disease · Germany | 2 | Completed | Dr. Falk Pharma | Jun 7, 2023 | 186 |
How it is read
Names in the registry
- “ZED1227 + SIGE”, 1 entry
- “TAK-227”, 1 entry
- “ZED1227”, 1 entry
Conditions, from the studies’ own filings
- Celiac Disease, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.